GlassScriptPhysician profile
Kyndall Petry
NPI 1134875842
$2,551.64
in general payments reported to CMS, 2019-2025
26 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $240 · 2023: $965 · 2024: $562 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.01 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $485.78 | 2022-2025 | |
| Pfizer INC. | $179.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.86 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $159.11 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $110.49 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $110.47 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $104.28 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $91.27 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.63 | 2023-2025 | Jardiance, Synjardy |
| Sumitomo Pharma America, INC. | $73.10 | 2023-2024 | Gemtesa |
| Amgen INC. | $50.12 | 2022-2023 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $45.01 | 2023 | Rexulti |
| Abbott Laboratories | $43.88 | 2023-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $42.21 | 2023 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $40.57 | 2023 | Omnipod |
| Currax Pharmaceuticals LLC | $29.90 | 2023 | Contrave, Nexlizet, Nexletol |
| Alnylam Pharmaceuticals INC. | $27.45 | 2025 | Givlaari |
| Harmony Biosciences LLC | $23.62 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.61 | 2025 | Pyrukynd |
| Shield Therapeutics INC | $20.69 | 2024 | |
| Daiichi Sankyo INC. | $18.92 | 2022 | |
| Eisai INC. | $17.13 | 2024 | |
| Sanofi Pasteur INC. | $14.76 | 2023 | |
| Astellas Pharma US INC | $14.15 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyndall Petry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.